Media Coverage header image

Media Coverage

Advanced Search
  • 11192019
    MSN Health & Fitness

    Among more than 100,000 patients enrolled in both commercial insurance and Medicare Advantage programs, researchers found that the annual percentage undergoing tapering doubled between 2008 and 2017.[CR-LF][CR-LF]In another recent survey, which was conducted by Quest Diagnostics and the Center on Addiction, more than four out of five doctors said they were reluctant to take on patients using prescribed opioids. They also said the opioid crisis made it more difficult to treat patients in pain.

  • 11192019
    American Banking & Market News

    Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

  • 11142019
    Physician's Briefing

    Neither vitamin D nor marine omega-3 (n-3) fatty acid supplementation significantly reduces the rate of first heart failure hospitalization, according to a research letter published online Nov. 11 in Circulation to coincide with the annual meeting of the American Heart Association, held from Nov. 16 to 18 in Philadelphia.[CR-LF][CR-LF]Luc Djoussé, M.D., Sc.D., from Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues examined the effects of vitamin D and n-3 supplements on the incidence of heart failure hospitalization in a large, multi-ethnic cohort with 25,871 adults; 36 participants with prevalent heart failure were excluded.[CR-LF]Two authors disclosed financial ties to Quest Diagnostics, which measured serum 25-hydroxyvitamin D and serum omega-3 index at no cost; several pharmaceutical companies provided the study agents, matching placebos, and packaging.

  • 11142019
    Financial Times - FT.com

    A laboratory test that evaluates high-density lipoprotein (HDL) cholesterol function provides unique and novel information for assessing cardiovascular disease risk, according to data presented today (Abstract #1020) by Quest Diagnostics (NYSE: DGX) at the 2019 American Heart Association Scientific Sessions. The study is one of four the company will present at the conference, which runs November 16-18, in Philadelphia (Booth #1502).

  • 11082019
    NJBIZ Online

    Technology’s role in health care is creating new opportunities for established health care providers and insurers, as well as entrepreneurs.[CR-LF][CR-LF]That was the conclusion of a panel of health care experts at the Newark Regional Business Partnership series entitled: How Technology is Changing Health Care on Thursday in Newark.[CR-LF]Dr. Damian Alagia, chief clinical officer, Health Systems at Quest Diagnostics said that for an entrepreneur it is a great time to be in medicine.[CR-LF][CR-LF]“Anyplace in health care where you can put the patient in the center of everything you can do … if you look at health systems and doctors offices that are successful, they are the ones that kept the patients at the center, everything emanates from that patient care model. If you get that right everything else falls into place,” said Alagia.

Show 5102550100 per page